These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22146238)

  • 1. Atorvastatin does not affect ischaemia-induced phosphatidylserine exposition in humans in-vivo.
    Wouters CW; Meijer P; Janssen CI; Frederix GW; Oyen WJ; Boerman OC; Smits P; Rongen GA
    J Atheroscler Thromb; 2012; 19(3):285-91. PubMed ID: 22146238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II type 1 receptor blockade does not enhance apoptotic cell death during ischemia and reperfusion in humans in vivo.
    Meijer P; Wouters CW; Oyen WJ; Boerman OC; Scheffer GJ; Smits P; Rongen GA
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):702-6. PubMed ID: 21423028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans.
    Rongen GA; Oyen WJ; Ramakers BP; Riksen NP; Boerman OC; Steinmetz N; Smits P
    Circulation; 2005 Jan; 111(2):173-8. PubMed ID: 15623546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
    Riksen NP; Oyen WJ; Ramakers BP; Van den Broek PH; Engbersen R; Boerman OC; Smits P; Rongen GA
    Clin Pharmacol Ther; 2005 Jul; 78(1):52-9. PubMed ID: 16003293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: a pilot study.
    Engbersen R; Riksen NP; Mol MJ; Bravenboer B; Boerman OC; Meijer P; Oyen WJ; Tack C; Rongen GA; Smits P
    Cardiovasc Diabetol; 2012 Oct; 11():124. PubMed ID: 23051145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.
    Buller N; Gillen D; Casciano R; Doyle J; Wilson K
    Pharmacoeconomics; 2003; 21 Suppl 1():25-32. PubMed ID: 12648032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease.
    Claeys MJ; Cosyns B; Hoffer E; Carlier M; Missault L; Cools F; De Meester A; Vermeersch P; Gobin E; Dewit B;
    Acta Cardiol; 2004 Jun; 59(3):269-74. PubMed ID: 15255458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular basis for the treatment of myocardial ischemia study: trial design and baseline characteristics.
    Stone PH; Lloyd-Jones DM; Johnstone M; Carlson W; Rubenstein J; Creager M; Frei B; Sopko G; Clark ME; Maccallum G; Kinlay S; Orav J; Selwyn AP
    Am Heart J; 2004 May; 147(5):875-82. PubMed ID: 15131545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of atorvastatin on the angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin (STZ) induced diabetic rats.
    Chaudagar KK; Mehta AA
    Can J Physiol Pharmacol; 2014 Apr; 92(4):338-49. PubMed ID: 24708217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial.
    Suleiman M; Koestler C; Lerman A; Lopez-Jimenez F; Herges R; Hodge D; Bradley D; Cha YM; Brady PA; Munger TM; Asirvatham SJ; Packer DL; Friedman PA
    Heart Rhythm; 2012 Feb; 9(2):172-8. PubMed ID: 21920481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study.
    Weisshaar S; Litschauer B; Kerbel T; Wolzt M
    Int J Cardiol; 2018 Mar; 255():1-7. PubMed ID: 29288055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder.
    Haghighi M; Khodakarami S; Jahangard L; Ahmadpanah M; Bajoghli H; Holsboer-Trachsler E; Brand S
    J Psychiatr Res; 2014 Nov; 58():109-14. PubMed ID: 25130678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study.
    Kanaki AI; Sarafidis PA; Georgianos PI; Stafylas PC; Kanavos K; Tziolas IM; Lasaridis AN
    J Hum Hypertens; 2012 Oct; 26(10):577-84. PubMed ID: 21881597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine prevents protection in two human models of ischemic preconditioning.
    Riksen NP; Zhou Z; Oyen WJ; Jaspers R; Ramakers BP; Brouwer RM; Boerman OC; Steinmetz N; Smits P; Rongen GA
    J Am Coll Cardiol; 2006 Aug; 48(4):700-7. PubMed ID: 16904537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial.
    Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Cardinal JW; Coombes JS
    Nephrol Dial Transplant; 2012 Jan; 27(1):182-9. PubMed ID: 21543653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin in pulmonary arterial hypertension (APATH) study.
    Zeng WJ; Xiong CM; Zhao L; Shan GL; Liu ZH; Xue F; Gu Q; Ni XH; Zhao ZH; Cheng XS; Wilkins MR; He JG;
    Eur Respir J; 2012 Jul; 40(1):67-74. PubMed ID: 22362846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U; Gathof BS
    Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.